Products
Torvutatug Biosimilar Antibody-Drug Conjugate (Folate Receptor Alpha) for Research
Cat No.: GMP-Bios-INN-1423
Anti-FOLR1 therapeutic antibody (Pre-made Torvutatug biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Torvutatug (development code AZD-5335) is a monoclonal antibody-drug conjugate targeting folate receptor alpha (FOLR1). It is developed by AstraZeneca for Solid tumours in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1423-1mg | 1mg | 4635 |
| GMP-Bios-INN-1423-10mg | 10mg | |
| GMP-Bios-INN-1423-100mg | 100mg | |
| GMP-Bios-INN-1423-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Torvutatug biosimilar, Whole mAb ADC, Anti-FOLR1 Antibody: Anti-FOLR1/Folate receptor alpha/FR-alpha/Adult folate-binding protein (FBP) therapeutic antibody |
| INN Name | Torvutatug |
| Target | FOLR1 |
| Format | Whole mAb ADC |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | AstraZeneca |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
